ASTRO-AstraZeneca SCLC Therapy Challenge RFP Grant
Funding Amount
US $175,000 - US $375,000
Deadline
Deadline not published
Grant Type
Foundation
Overview
The ASTRO-AstraZeneca SCLC Therapy Challenge RFP aims to enhance research on limited-stage small cell lung cancer (LS-SCLC) through innovative combination therapies, particularly integrating immunotherapy with advanced radiation techniques. Proposals are encouraged to explore various aspects, including care patterns, treatment workflows, prognostic biomarkers, and toxicity management. The target budget for projects ranges from $175,000 to $375,000, with consideration given to higher requests based on scientific merit, fostering significant advancements in radiation oncology.
The purpose of this grant is to advance collaborative research in the treatment of limited-stage small cell lung cancer (LS-SCLC), fostering leadership in radiation oncology through multimodality combination therapies, with a special focus on integrating immunotherapy and innovative radiation techniques.
Challenge Statement/Research Areas of Interest
How can treatment and outcomes for LS-SCLC be improved through the combination of immunotherapy (IO) and advanced radiation therapies?
Research proposals in the following topic areas are encouraged:
Analyzing care patterns for multimodality concurrent chemo-radiation (cCRT) combined with IOExploring optimal workflows for administering cCRT + IO in clinical settingsIdentifying prognostic biomarkers for predicting patient response to treatmentInvestigating disease relapse patterns and treatment efficacy (cCRT + IO vs. cCRT alone)Managing toxicities associated with combined treatmentsPilot studies using novel radiation methods (e.g., SBRT, hypofractionation) alongside cCRT + IOLeveraging AI for SCLC detection and predicting complications like pneumonitisEvaluating the role of prophylactic cranial irradiation (PCI) in the era of combined therapies
Studies of interest may evaluate the following:
Clinical outcomes (i.e., PFS, MFS, local control, etc.)Biomarker identificationSafety/Adverse Events (AEs)Patient-Reported Outcomes (PROs)Translational research such as exploratory biomarkers and mechanistic studies
Budget
The target budget for each individual project grant is between U.S. $175,000 to $375,000 (total costs, which include both direct and indirect costs). However, individual projects requesting higher amounts will be considered based on scientific merit and funding availability. Overhead (indirect cost) rates of up to 25% of the total proposed project budget are allowed.
What American Society for Radiation Oncology actually gave
Source: IRS Form 990, 2025
- Grants in 2025
- 10
- Total given
- $696K
- Median grant
- $38K
- Range
- $8,500–$363K
- By dollars: Georgia 52%, Missouri 14%, New York 7%. Top recipient cities: Atlanta, GA; St. Louis, MO; Alexandria, VA.
- 0% of grants with a stated purpose were for general or operating support.
- 40% of recipients were new grantees, not repeat recipients.
Example grants
American Cancer Society Inc · Atlanta, GA
Research grant award
$363K
Washington University · St Louis, MO
Research grant award
$100K
American Association of Physicists in Medicine · Alexandria, VA
Research grant award
$50K
The General Hospital Corporation · Boston, MA
Research grant award
$50K
NRG Oncology Foundation · Philadelphia, PA
Research grant award
$25K
Focus Areas & Funding Uses
Fields of Work
- Science research
- Cancer
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
ASTRO-PCF Young Investigator Award Grant
American Society for Radiation Oncology
Amount
US $225,000
Deadline
Deadline not published
ACS-ASTRO Felix Feng, MD Clinician Scientist Development Award Grant
American Society for Radiation Oncology
Amount
US $729,000
Deadline
Deadline not published
ASTRO-AAPM Physics Resident/Post-Doctoral Fellow Seed Grant (1 year)
American Society for Radiation Oncology
Amount
Up to US $100,001
Deadline
Deadline not published
Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
January 7, 2028
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $500,000
Deadline
January 7, 2028
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
November 6, 2026
Ready to apply for ASTRO-AstraZeneca SCLC Therapy Challenge RFP Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found ASTRO-AstraZeneca SCLC Therapy Challenge RFP Grant. Now let's win it.